XML 88 R78.htm IDEA: XBRL DOCUMENT
v3.19.2

Commitments and Contingencies - Contingencies - Additional Information (Detail) € in Millions, $ in Millions, $ in Millions |  |  |  |  | 1 Months Ended | 6 Months Ended | 12 Months Ended |  |  |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Oct. 04, 2018 USD ($) | Jun. 27, 2018 CAD ($) | Aug. 21, 2017 USD ($) | Jul. 15, 2015 USD ($) | May 31, 2019 USD ($) | Nov. 30, 2018 USD ($) | Nov. 30, 2017 USD ($) | Jul. 31, 2015 USD ($) | Sep. 30, 2013 USD ($) | Apr. 30, 2013 USD ($) | Aug. 31, 2012 USD ($) | Dec. 31, 2010 USD ($) | Nov. 30, 2009 USD ($) | Aug. 31, 2008 USD ($) | Jun. 30, 2019 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2014 CAD ($) | Jun. 30, 2019 CAD ($) | Jun. 30, 2019 EUR (€) | Jun. 30, 2019 USD ($) | Dec. 31, 2016 USD ($) | May 31, 2015 USD ($) | Dec. 31, 2014 USD ($) | Mar. 31, 2014 USD ($) | Aug. 31, 2013 USD ($) | Jan. 31, 2009 USD ($) | Jul. 31, 2008 USD ($) | Feb. 28, 2005 USD ($)
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damages assessment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 235.5 |  |  |  |  |  |  |  |
Sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 94 |  |  |  |  |  |  |  |  |  |  |
Modafinil payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,200.0 |  |  |  |  |  |
Modafinil Euro sales | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 46.5 |  |  |  |  |  |  |  |  |
Annual sales at the time of settlement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 350.0 |  |
Annual sales of Effexor |  |  | $ 2,600.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of Lamictal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,300.0 | $ 950.0
Annual sales of Niaspan |  |  |  |  |  |  |  |  | $ 1,100.0 | $ 416.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of Aggrenox |  |  |  | $ 455.0 |  |  |  |  |  |  |  |  |  | $ 340.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of Actos |  |  |  |  |  |  |  |  |  |  | $ 2,800.0 | $ 3,700.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of Acto plus |  |  |  |  |  |  |  |  |  |  | $ 430.0 | $ 500.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of Namenda |  |  |  |  |  |  |  | $ 550.0 |  |  |  |  | $ 1,100.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of Intuniv |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 335.0 |  | $ 327.0 |  |  |  |  |
Sales |  |  |  |  |  | $ 1,300.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales |  |  |  |  |  |  | $ 459.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Compensatory damages and penalties |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 12.4 |  |  |
Punitive damages |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 17.9 |  |  |  |
Litigation settlement amount | $ 135.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 22.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Annual Sales Of Sensipar |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,400.0 |  |  |  |  |  |  |  |  |  |  |  |
opioid litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount |  |  |  |  | $ 85.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Eosinophilic Esophagitis [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damage claimed |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 200.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Eosinophilic Esophagitis [Member] | United States [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damage claimed |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Eosinophilic Esophagitis [Member] | Europe [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damage claimed |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.0 |  |  |  |  |  |  |  |  |  |  |  |  |
AbbVie [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Legal fees |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 448.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Janssen and Millennium [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum damages payable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 200 |  |  |  |  |  |  |  |  |  |
Litigation settlement awarded from other party |  | $ 5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AndroGel Rate at 1% [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales at the time of settlement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 140.0 |  |

X
- Definition Annual sales at time of settlement. + References No definition available. + Details
Name: | teva_AnnualSalesAtTimeOfSettlement
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Annual sales of Acto plus. + References No definition available. + Details
Name: | teva_AnnualSalesOfActoplus
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of Actos. + References No definition available. + Details
Name: | teva_AnnualSalesOfActos
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of Aggrenox. + References No definition available. + Details
Name: | teva_AnnualSalesOfAggrenox
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of Aloxi. + References No definition available. + Details
Name: | teva_AnnualSalesOfAloxi
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of effexor. + References No definition available. + Details
Name: | teva_AnnualSalesOfEffexor
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of Intuniv. + References No definition available. + Details
Name: | teva_AnnualSalesOfIntuniv
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Annual sales of Lamictal. + References No definition available. + Details
Name: | teva_AnnualSalesOfLamictal
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Annual sales of Namenda. + References No definition available. + Details
Name: | teva_AnnualSalesOfNamenda
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of Niaspan. + References No definition available. + Details
Name: | teva_AnnualSalesOfNiaspan
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents Annual Sales Of Sensipar. + References No definition available. + Details
Name: | teva_AnnualSalesOfSensipar
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual Sales Of Velcade + References No definition available. + Details
Name: | teva_AnnualSalesOfVelcade
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual Sales of Zytiga + References No definition available. + Details
Name: | teva_AnnualSalesOfZytiga
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Commitment And Contingencies [Line Items] + References No definition available. + Details
Name: | teva_CommitmentAndContingenciesLineItems
Namespace Prefix: | teva_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Compensatory damages and penalties. + References No definition available. + Details
Name: | teva_CompensatoryDamagesAndPenalties
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Damages assessment. + References No definition available. + Details
Name: | teva_DamagesAssessment
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Modafinil Euro sales. + References No definition available. + Details
Name: | teva_ModafinilEuroSales
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Modafinil payment. + References No definition available. + Details
Name: | teva_ModafinilPayment
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Punitive damages. + References No definition available. + Details
Name: | teva_PunitiveDamages
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 + Details
Name: | us-gaap_LegalFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount awarded from other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedFromOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount awarded to other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of damages paid to the plaintiff in the legal matter. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyDamagesPaidValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The value (monetary amount) of the award the plaintiff seeks in the legal matter. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyDamagesSoughtValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reflects the estimated amount of loss from the specified contingency as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248 + Details
Name: | us-gaap_LossContingencyEstimateOfPossibleLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | srt_LitigationCaseAxis=teva_OpioidLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=teva_AbbVieMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=teva_JanssenAndMillenniumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePercentageMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |